1
|
Tolan NV, Kang P, Chai PR, Erickson TB, Hayes BD, Uljon SN, Demetriou CA, Melanson SEF. Impact of COVID-19 on Drug Positivity Rates in the Emergency Departments in Boston and Surrounding Areas. J Appl Lab Med 2024; 9:1064-1070. [PMID: 39076019 DOI: 10.1093/jalm/jfae076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2024] [Accepted: 06/17/2024] [Indexed: 07/31/2024]
Abstract
BACKGROUND The COVID-19 pandemic reportedly had a significant impact on drug and alcohol use. In this article, we determine positivity rates for urine drugs of abuse and blood alcohol in 5 emergency departments (ED) in the greater Boston metropolitan area over a 4-year period (pre-, during, and post-COVID-19 pandemic). METHODS Positivity rates for the urine drug screening (UDS) panel and blood alcohol concentration (>80 mg/dL; over the legal limit in MA) were calculated in patients presenting to one of the 5 ED (2 academic hospitals in Boston, MA and 3 community hospitals outside Boston, MA) during each of the 4 different time periods: pre-COVID (January 1, 2019 to December 31, 2019), stay-at-home (March 24, 2020 to May 18, 2020), during COVID (May 19, 2020 to March 28, 2021), and post-COVID (May 12, 2023 to August 31, 2023). Trend analysis was performed. Additionally, positivity rates during and post-COVID were compared to pre-COVID to determine any significant changes in drug positivity. RESULTS Stimulant (amphetamines and cocaine), cannabinoid, and methadone positivity increased during the pandemic and cocaine, cannabinoid, and methadone positivity remains elevated. By contrast, benzodiazepine and opioid (opiates, fentanyl, oxycodone) positivity decreased and remains lower post-COVID compared to pre-COVID. Patients in the ED with blood alcohol over the legal limit decreased both during and post-COVID. CONCLUSION Our study showed that the COVID-19 pandemic significantly affected drug and alcohol positivity rates in patients presenting to the ED in greater Boston area. We encourage other institutions to perform similar analyses to help determine local drug use patterns and appropriate composition of UDS panels.
Collapse
Affiliation(s)
- Nicole V Tolan
- Department of Pathology, Brigham and Women's Hospital, Boston, MA, United States
- Harvard Medical School, Boston, MA, United States
| | - Phillip Kang
- Department of Pathology, Brigham and Women's Hospital, Boston, MA, United States
| | - Peter R Chai
- Harvard Medical School, Boston, MA, United States
- Department of Emergency Medicine, Division of Medical Toxicology, Brigham and Women's Hospital, Boston, MA, United States
- The Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, United States
- The Fenway Institute, Boston, MA, United States
| | - Timothy B Erickson
- Harvard Medical School, Boston, MA, United States
- Department of Emergency Medicine, Division of Medical Toxicology, Brigham and Women's Hospital, Boston, MA, United States
- Harvard Humanitarian Initiative, Cambridge, MA, United States
| | - Bryan D Hayes
- Harvard Medical School, Boston, MA, United States
- Department of Pharmacy, Massachusetts General Hospital, Boston, MA, United States
| | - Sacha N Uljon
- Harvard Medical School, Boston, MA, United States
- Department of Pathology, Massachusetts General Hospital, Boston, MA, United States
| | - Christiana A Demetriou
- Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus
- The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
| | - Stacy E F Melanson
- Department of Pathology, Brigham and Women's Hospital, Boston, MA, United States
- Harvard Medical School, Boston, MA, United States
| |
Collapse
|
2
|
Giménez-Palomo A, Fico G, Borràs R, Sagué-Vilavella M, Gómez-Ramiro M, Fortea A, Fortea L, Vázquez M, Vieta E. Increasing prevalence of self-harm, suicidal behavior and suicidal ideation throughout a three-year period in the context of COVID-19 pandemic in Spain. Psychiatry Res 2024; 339:116015. [PMID: 38943785 DOI: 10.1016/j.psychres.2024.116015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 06/03/2024] [Accepted: 06/08/2024] [Indexed: 07/01/2024]
Abstract
The COVID-19 pandemic had a great impact on mental health both in the general population and in individuals with preexisting mental disorders. Lockdown, social restrictions, changes in daily habits and limited access to health services led to changes in consultations in mental health services. This study aimed to determine changing trends in psychiatric admissions by the inclusion of adult patients admitted to the Emergency Department (ED) of Hospital Clínic of Barcelona between 2019 and 2021. Acute admissions, social issues and psychiatric diagnoses were compared between years, seasons and considering the interaction between both years and seasons. A total of 13,677 individuals were included in the analysis. An overall reduction in consultations to the ED and a higher proportion of acute admissions was observed in 2020 in context of the COVID-19 outbreak. Increased prevalence of sleeping disorders and substance use disorders was found in 2020. Self-harming behavior, suicidal thoughts and suicidal behavior showed an increasing tendency over time, with their highest rates in 2021. Prevention and management strategies should be considered in order to address increasing needs in mental health care.
Collapse
Affiliation(s)
- Anna Giménez-Palomo
- Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona. c. Villarroel, 170, Barcelona, 08036, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), c. Villarroel, 170, Barcelona, 08036, Spain; Institute of Neurosciences (UBNeuro), Spain
| | - Giovanna Fico
- Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona. c. Villarroel, 170, Barcelona, 08036, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), c. Villarroel, 170, Barcelona, 08036, Spain; Institute of Neurosciences (UBNeuro), Spain
| | - Roger Borràs
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), c. Villarroel, 170, Barcelona, 08036, Spain
| | - Maria Sagué-Vilavella
- Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona. c. Villarroel, 170, Barcelona, 08036, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), c. Villarroel, 170, Barcelona, 08036, Spain; Institute of Neurosciences (UBNeuro), Spain
| | - Marta Gómez-Ramiro
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), c. Villarroel, 170, Barcelona, 08036, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain; Department of Psychiatry, Hospital Alvaro Cunqueiro, Servizo Galego de Saúde (SERGAS), Vigo, Spain; Translational Neuroscience Research Group, Galicia Sur Health Research Institute (IISGS), Spain
| | - Adriana Fortea
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), c. Villarroel, 170, Barcelona, 08036, Spain; Institute of Neurosciences (UBNeuro), Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain
| | - Lydia Fortea
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), c. Villarroel, 170, Barcelona, 08036, Spain; Institute of Neurosciences (UBNeuro), Spain
| | - Mireia Vázquez
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), c. Villarroel, 170, Barcelona, 08036, Spain; Institute of Neurosciences (UBNeuro), Spain; Psychiatry and Psychology Service, Hospital Clínic de Barcelona. c. Villarroel, 170, Barcelona, 08036, Spain
| | - Eduard Vieta
- Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona. c. Villarroel, 170, Barcelona, 08036, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), c. Villarroel, 170, Barcelona, 08036, Spain; Institute of Neurosciences (UBNeuro), Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain; Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), c. Casanova, 143, Barcelona, 08036, Spain.
| |
Collapse
|
3
|
Sampaio GR, Lima GS, de Souza SB, Soares DDM. Use of psychoactive substances among university students from 2019 to 2020: A systematic review. Brain Behav Immun Health 2024; 35:100724. [PMID: 38292320 PMCID: PMC10827412 DOI: 10.1016/j.bbih.2024.100724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2023] [Revised: 12/18/2023] [Accepted: 01/05/2024] [Indexed: 02/01/2024] Open
Abstract
Psychoactive substances act on the central nervous system producing changes in mental processes, such as perception, consciousness, cognition or mood and emotions. The present study aims to identify: (i) the most used psychoactive substances, (ii) how psychoactive substances are acquired, (iii) and possible reasons for the use of psychoactive substances amongst university students. A literature search was carried out without language restrictions and included articles published between 2019 and 2020 in journals indexed in the electronic databases of Pubmed and Scielo. The inclusion criteria considered were: (i) original articles, (ii) studies carried out with university students, (iii) providing data on the use of psychoactive substances. 15 studies were included in this review, of which: 4 studies addressed possible reasons that lead to use of psychoactive substances, 10 studies reported usage profile and demographic data, and 1 study addressed how students acquire psychoactive substances. Reasons that led to the consumption of psychoactive substances include: feelings of loneliness after moving away from family; difficulty making new friends; poor academic performance and susceptible environment to acquisition of these substances. In the selected studies, alcohol was identified as the main drug used. In light of the findings reported in this review, new prevention and harm reduction measures can be formulated, based mainly on the reasons that lead to the use of psychoactive drugs, consumption patterns and how the drugs were acquired by university students.
Collapse
Affiliation(s)
- Gustavo Reis Sampaio
- Post-Graduation Program in Pharmacy, Faculty of Pharmacy, Federal University of Bahia, 40170-115, Salvador, Bahia, Brazil
| | - Gabriel Silva Lima
- Post-Graduation Program in Pharmacy, Faculty of Pharmacy, Federal University of Bahia, 40170-115, Salvador, Bahia, Brazil
| | - Suzana Braga de Souza
- Institute of Health Sciences, Federal University of Bahia, 40110-040, Salvador, Bahia, Brazil
| | - Denis de Melo Soares
- Post-Graduation Program in Pharmacy, Faculty of Pharmacy, Federal University of Bahia, 40170-115, Salvador, Bahia, Brazil
| |
Collapse
|